Patents by Inventor Robert Hollingsworth

Robert Hollingsworth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190283632
    Abstract: A system, method and apparatus for a transit seating system including multiple seat frames, each seat frame including, at least one forward support and at least one rearward support. The at least one forward support and the at least one rearward support are capable of being detachably secured to a transit vehicle floor. A seat back height track system is vertically and slideably coupled to the seat frame. A seat back subframe is coupled to the seat back height track system. A seat base frame is coupled to the seat back height track system through a seat hinge. The at least one forward support is capable of overlapping the at least one rearward support when at least two of the seat frames are in a nested or fully compressed or stowed configuration.
    Type: Application
    Filed: March 15, 2018
    Publication date: September 19, 2019
    Inventors: Ritchie Dave Hollingsworth, Joseph D Mello, Luke Daniel Mielke, Christopher Luis San Nicolas, Jonathan William Rich, Samuel Robert Thompson
  • Patent number: 10287362
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 14, 2019
    Assignee: MedImmune Limited
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20180194858
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Application
    Filed: February 23, 2018
    Publication date: July 12, 2018
    Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui Huang, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
  • Patent number: 9938356
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: April 10, 2018
    Assignee: MEDIMMUNE LIMITED
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20160194407
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Application
    Filed: November 9, 2015
    Publication date: July 7, 2016
    Inventors: Carl HAY, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20060227759
    Abstract: In various embodiments, devices coupled to upstream ports may enumerate the USB switching hub according to the total number of downstream ports on the USB switching hub. In some embodiments, when a first upstream port is communicating with a first downstream port, status registers coupled to the second upstream port may indicate to the second upstream device that the first downstream port is disconnected. By enumerating the USB switching hub according to the total number of downstream ports, the upstream devices may not have to re-enumerate the hub (and correspondingly each device coupled to the hub) each time a downstream device is switched. In some embodiments, an intelligent port routing switch may delay switching communications for the downstream port if there is an active transfer in progress between a related downstream port and an upstream port.
    Type: Application
    Filed: June 14, 2006
    Publication date: October 12, 2006
    Inventors: Mark Bohm, Mark Fu, Henry Wurzburg, James Bowles, Robert Hollingsworth, Drew Dutton, Akhlesh Nigam
  • Publication number: 20060059293
    Abstract: In various embodiments, a USB switching hub may switch between a first configuration and a second configuration to switch access between two or more upstream ports on the hub to at least a subset of downstream ports on the hub. In some embodiments, the hub may include a downstream routing controller to switch between the first configuration and the second configuration. In some embodiments, configurations (e.g., hardwired in the USB switching hub) may be switched as determined by logic on the USB switching hub.
    Type: Application
    Filed: September 14, 2004
    Publication date: March 16, 2006
    Inventors: Henry Wurzburg, James Bowles, Robert Hollingsworth, Mark Bohm, Drew Dutton
  • Publication number: 20060056401
    Abstract: In various embodiments, devices coupled to upstream ports may enumerate the USB switching hub according to the total number of downstream ports on the USB switching hub. In some embodiments, when a first upstream port is communicating with a first downstream port, status registers coupled to the second upstream port may indicate to the second upstream device that the first downstream port is disconnected. By enumerating the USB switching hub according to the total number of downstream ports, the upstream devices may not have to reenumerate the hub (and correspondingly each device coupled to the hub) each time a downstream device is switched. In some embodiments, an intelligent port routing switch may delay switching communications for the downstream port if there is an active transfer in progress between a related downstream port and an upstream port.
    Type: Application
    Filed: April 6, 2005
    Publication date: March 16, 2006
    Inventors: Mark Bohm, Mark Fu, Henry Wurzburg, James Bowles, Robert Hollingsworth, Drew Dutton